Biogen
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Clinical Trials
522
Trial Phases
6 Phases
Drug Approvals
9
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (418 trials with phase data)• Click on a phase to view related trials
A Study to Learn if Taking BIIB141 (Omaveloxolone) Affects How Omeprazole is Processed in the Body and About BIIB141's Safety in Healthy Adults Aged 18 to 55
- First Posted Date
- 2025-09-02
- Last Posted Date
- 2025-09-19
- Lead Sponsor
- Biogen
- Target Recruit Count
- 22
- Registration Number
- NCT07149415
- Locations
- 🇺🇸
Austin Clinical Research Unit, Austin, Texas, United States
A Study to Learn About the Safety of BIIB142 and How it is Processed in the Body of Healthy Adult Participants Aged 18 to 55 Years Old
- Conditions
- Healthy Volunteer
- Interventions
- Drug: BIIB142Drug: BIIB142-Matching Placebo
- First Posted Date
- 2025-08-21
- Last Posted Date
- 2025-09-11
- Lead Sponsor
- Biogen
- Target Recruit Count
- 78
- Registration Number
- NCT07133828
- Locations
- 🇺🇸
PPD Development, LP, Las Vegas, Nevada, United States
A Study to Learn More About How Zuranolone Affects Postpartum Depression Symptoms in Participants Who Took it Within 1 Year After The End of Their Pregnancy
- First Posted Date
- 2025-07-02
- Last Posted Date
- 2025-08-03
- Lead Sponsor
- Biogen
- Target Recruit Count
- 200
- Registration Number
- NCT07047820
- Locations
- 🇺🇸
CVS Health, Woonsocket, Rhode Island, United States
A Study to Learn How BIIB141 (Omaveloxolone) is Processed in the Body When Taken as Capsules Compared to Sprinkled on Yogurt in Healthy Adults Aged 18 to 55
- First Posted Date
- 2025-06-13
- Last Posted Date
- 2025-09-22
- Lead Sponsor
- Biogen
- Target Recruit Count
- 52
- Registration Number
- NCT07019064
- Locations
- 🇺🇸
Trialmed formerly PPD, Austin Clinic, Austin, Texas, United States
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
- Conditions
- Primary Membranous Nephropathy
- Interventions
- First Posted Date
- 2025-05-08
- Last Posted Date
- 2025-07-28
- Lead Sponsor
- Biogen
- Target Recruit Count
- 180
- Registration Number
- NCT06962800
- Locations
- 🇺🇸
James J Peters Veterans Administration Medical Center - NAVREF - PPDS, Bronx, New York, United States
🇺🇸Academic Medical Research Institute, Los Angeles, California, United States
🇺🇸Elixia Health - Michigan Kidney Consultants, LLC - Elixia - PPDS, Pontiac, Michigan, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 101
- Next
News
Indivi and Clouds of Care Partner to Advance Deep Phenotyping Technologies for Alzheimer's and Parkinson's Drug Development
Two TechBio companies, Indivi and Clouds of Care, announced a strategic partnership to advance precision medicine tools in early-phase neuroscience drug development for Alzheimer's and Parkinson's disease.
CD40-Targeted Therapies Advance Toward First Approval by 2027 with Over 35 Candidates in Clinical Development
Over 35 CD40-targeted therapies are currently in clinical trials, with the first approval expected by 2027 according to new market research.
Stoke Therapeutics Appoints Ian Smith as CEO as Phase 3 Trial for Dravet Syndrome Treatment Advances
Stoke Therapeutics has appointed Ian Smith as Chief Executive Officer after he served as Interim CEO since March 2025, bringing over 30 years of rare disease drug development experience.
Ultragenyx Appoints Eric Olson as Chief Business Officer to Lead Rare Disease Pipeline Expansion
Ultragenyx Pharmaceutical appointed Eric Olson as Chief Business Officer and Executive Vice President effective September 22, 2025, following Thomas Kassberg's planned retirement after 14 years with the company.
Biogen Acquires Alcyone Therapeutics for $85M to Advance Implantable Drug Delivery System for Neurological Therapies
Biogen will acquire Alcyone Therapeutics for $85 million upfront plus development milestones to gain full rights to the ThecaFlex DRx implantable drug delivery system.
Drug Hunter Secures Seed Investment to Expand Knowledge Platform for Pharmaceutical R&D
Drug Hunter, a knowledge platform serving over 200 pharmaceutical R&D organizations including Eli Lilly, Biogen, and NIH, announced seed funding led by Teamworthy Ventures to accelerate drug discovery insights.
FDA Moves to Eliminate Expert Advisory Panels for Individual Drug Reviews Under Trump Administration
The FDA under President Trump is abandoning its decades-old policy of convening outside expert panels to review individual drug applications, with officials claiming these meetings are redundant and time-consuming.
GE HealthCare Acquires Icometrix to Strengthen Brain MRI Analysis Capabilities for Alzheimer's Drug Monitoring
GE HealthCare has acquired brain analysis company Icometrix for an undisclosed sum to expand its Alzheimer's disease diagnostic capabilities.
FDA Accepts IND Application for BIIB142, First IRAK4 Degrader to Enter Clinical Development for Autoimmune Diseases
The FDA has accepted Biogen's IND application for BIIB142, an IRAK4 protein degrader developed through collaboration with C4 Therapeutics, marking the first IRAK4 degrader to advance toward clinical trials for autoimmune diseases.
FDA Approves Weekly Autoinjector for Eisai's Alzheimer's Drug Leqembi, Enabling At-Home Treatment
The FDA has approved a once-weekly autoinjector version of Eisai's Alzheimer's drug Leqembi, branded as Leqembi IQLIK, marking the first at-home dosing option for amyloid-based Alzheimer's therapy.